2 completed, 1 active not recruiting, 1 recruiting. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
Follow Palbociclib 125mg: new trials by email Literature Review of Palbociclib 125mg trials Research Report on Palbociclib 125mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study Palbociclib 125mg, Ribociclib 600mg, Ribociclib - Metastatic Breast Cancer | Phase 3 | Recruiting | American Society of Clinical Oncology | 500 | 2024-10-29 | 2026-10-06 |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Palbociclib 125mg, Standard endocrine therapy - Breast Cancer Recurrent | Phase 3 | Active not recruiting | ETOP IBCSG Partners Foundation | 405 | 2019-08-27 | 2026-09-03 |
| Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant Fulvestrant 500mg, Palbociclib 125mg, Goserelin 3.6 MG - Breast Neoplasm Female | Phase 3 | Completed | International Cancer Research Group, United Arab Emirates | 354 | 2017-12-20 | 2023-03-10 |
| PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Palbociclib 125mg, Aromatase Inhibitors, Fulvestrant Injectable Product - Metastatic Breast Cancer | Phase 3 | Completed | UNICANCER | 1017 | 2017-03-22 | 2025-11-18 |
Breast Neoplasms (3)
American Society of Clinical Oncology (1) · ETOP IBCSG Partners Foundation (1) · International Cancer Research Group, United Arab Emirates (1) · UNICANCER (1)
France (2) · Algeria (1) · Austria (1) · Egypt (1) · Hungary (1) · Italy (1) · Jordan (1) · Lebanon (1) · Morocco (1) · Saudi Arabia (1) · Spain (1) · Switzerland (1) · Tunisia (1) · United Arab Emirates (1) · United States (1)
Elisabetta Munzone, MD (1) · Jean-Marc Nabholtz, MD (1) · Julie Gralow, MD (1)
PMID 35241469, PMID 36183733, PMID 36680581
2016 (1), 2018 (1)